65,437 trials
Liver Transplantation
Primary: Incidence Rate of Composite Efficacy Failure From Randomization to Month 12 — 6.7; 24.2; 9.7 Percentage of participants
Depression
Primary: Hamilton Rating Scale for Depression (24 Question Version), a Standardized Assessment Tool for Measuring Severity of Depression Where 0 is the Minimum Score (no…
Cholangiocarcinoma of the Extrahepatic Bile Duct · Cholangiocarcinoma of the Gallbladder · Gastrointestinal Cancer
Primary: Number of Confirmed Tumor Responses. — 6; 0 participants
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Two Strains of Influenza Disease. — 11.3; 9.7; 10.2; 8.8 Titer
Parkinson's Disease
Primary: Incidence of Nausea and/or Vomiting During the Initial Titration of Apokyn® at the Visit on Day 1 — 21; 10; 109; 34 participants — p=0.09
Pain
Primary: Estimated Percentage of Misuse for Non-Therapeutic Reasons — 6.5 Percentage of Participants
Refractive Error
Primary: Percentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better. — 100; 100; 100 percentage of eyes
Prostate Cancer
Primary: Percentage of Participants With Composite Response — 0.0; 0.0; 2.4 Percentage of participants
Rheumatoid Arthritis
Primary: Numeric Index of American College of Rheumatology Response (ACR-N, N Shows the Percent Improvement) — 51.3; 53.8; 58.3 percent change
Pulmonary Embolism · Deep Vein Thrombosis · Venous Thromboembolism
Primary: Safety — 0 participants
Crohn's Disease
Primary: Incidence of Adverse Events — 7; 4; 1; 7 events
Prostatic Neoplasms
Primary: Progression-Free Survival (PFS) — 336.0; 232.0 Days — p=0.014
Emphysema · Alpha 1-antitrypsin Deficiency (AATD)
Primary: Subjects With Treatment-Emergent Adverse Events (TEAEs) — 23; 18 participants
Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline to Week 52 — -1.03; -0.66 Percent — p=<0.05
Type 2 Diabetes
Primary: Number of Subjects With Study Drug-Related Adverse Events — 9; 11; 9; 11 participants